Last update 26 Jun 2024
Maxacalcitol
Last update 26 Jun 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms 1α, 25-dihydroxy-22-oxavitamin D3, 22-oxacalcitriol, 22-オキサカルシトリオール + [7] |
Target |
Mechanism VDR agonists(Vitamin D receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (03 Jul 2000), |
Regulation- |
Login to view First Approval Timeline
Structure
Molecular FormulaC26H42O4 |
InChIKeyDTXXSJZBSTYZKE-ZDQKKZTESA-N |
CAS Registry103909-75-7 |
Related
5
Clinical Trials associated with MaxacalcitolPHARMACOKINETIC STUDY OF MAXACALCITOL IN TAIWANESE AND JAPANESE MALE HEALTHY VOLUNTEERS
PHARMACOKINETIC STUDY OF MAXACALCITOL IN TAIWANESE AND JAPANESE MALE HEALTHY VOLUNTEERS
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism
100 Clinical Results associated with Maxacalcitol
Login to view more data
100 Translational Medicine associated with Maxacalcitol
Login to view more data
100 Patents (Medical) associated with Maxacalcitol
Login to view more data
836
Literatures (Medical) associated with Maxacalcitol01 Feb 2024International wound journal
A prospective study to analyse the concentration of octenidine in hand wounds after disinfection by LC–MS /MS
Article
Author: Prost, Jean-Christophe ; Bovet, Cédric ; Vögelin, Esther ; Langen, Susanne ; Surke, Carsten ; Lötscher, Patrick
Abstract:
Toxic reactions can appear after pressurised flushing of soft tissue with octenidine (OCT) containing disinfectants. Their use for surgical disinfection could complicate the diagnosis of possible contamination. In patients with open lacerations of their hand's subcutaneous tissue samples were taken before and after surgical disinfection with Octenisept® and analysed by ultra‐high‐performance liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS). In 16 out of 20 tissue samples, OCT was detected after disinfection (lower limit of quantification (LLOQ)=10 pg/mL/mg). The concentration of OCT was below the LLOQ, estimation of mean of 0.6 pg/mL/mg (0.22–0.98 pg/mL/mg, 95%‐CI) before disinfection and mean of 179.4 pg/mL/mg (13.35–432.0 pg/mL/mg, 95%‐CI) after disinfection. This study shows that the disinfection of open wounds with Octenisept® leads to a quantifiable concentration of OCT in open wounds. In cases of suspected OCT‐mediated toxic reaction, the use of antiseptics containing OCT should be avoided.
01 Jan 2024The Journal of hospital infection
Efficacy of octenidine- and chlorhexidine-based wash-mitts against Candida albicans and Candida auris – a comparative study
Article
Author: Tan, C K ; Gugsch, F ; Paßvogel, L ; Steinhauer, K ; Oh, D Y
BACKGROUND:
Management of outbreaks of the newly emerging pathogen Candida auris may include use of antimicrobial wash-mitts for decolonization. However, currently there is little clinical evidence to support the wide adoption of 'whole-body decolonization' as part of the protocol to effectively manage C. auris outbreaks. The aim of this study was to investigate the chemical tolerance of C. auris compared with the surrogate test organism Candida albicans as established in the European Standards (EN).
METHODS:
Two commercially available antiseptic-impregnated wash-mitts based on either chlorhexidine digluconate (CHG) or octenidine dihydrochloride (OCT) were studied. Comparison of susceptibility of C. auris and C. albicans was investigated based on the standardized test protocol EN 13624. Experiments were conducted using the impregnation liquid squeezed from the wash-mitts at a contact time of 30 s at different concentrations between 0.5% and 97% in the presence of low organic soiling.
FINDINGS:
Yeasticidal efficacy according to EN 13624 was found for the OCT wash-mitts at 30 s at ≥10% concentration with C. albicans. In comparison, reduction ≥4 log10 was found at a much lower concentration of ≥1% for both C. auris strains. For the CHG wash-mitts, efficacy against C. albicans was below 2 log10 reduction at 97% concentration within 30 s. Efficacy against the two C. auris strains was around 3 log10 reduction.
CONCLUSION:
Both C. auris strains were found to be significantly more susceptible when compared with C. albicans. Data also demonstrate that not all antiseptic-impregnated wash-mitts are equally effective against C. auris with OCT having a higher efficacy compared with CHG.
31 Dec 2023Journal of medical economics
Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective
Article
Author: Ektare, Varun ; Jamil, Khurram ; Niewoehner, John ; Corman, Shelby ; Huang, Xingyue ; Carter, John A
BACKGROUND:
Hepatorenal syndrome (HRS) is characterized by severely reduced renal perfusion that precipitates rapid morbidity and mortality. Terlipressin is the only US Food and Drug Administration-approved treatment to improve kidney function for adults with HRS with a rapid reduction in kidney function. Prior to the approval of terlipressin, unapproved vasoconstrictive agents used in HRS treatment were octreotide/midodrine and norepinephrine with albumin.
METHODS:
A cohort decision-tree model representing a US hospital perspective assessed the clinical outcomes and direct medical costs (based primarily on hospital charges) of treating HRS with terlipressin + albumin (ALB) versus midodrine/octreotide (MID/OCT)+ALB, or norepinephrine (NorEp)+ALB. Treatment efficacy was defined by clinical response (complete/HRS reversal, partial, or no response) based on change of serum creatinine derived from published clinical trial reports. The proportions of patients with complete response were: terlipressin + ALB (36.2%), NorEp + ALB (19.1%), and MID/OCT + ALB (3.1%). Model outcomes included utilization of HRS-related healthcare resources (hospital and intensive care, outpatient and emergency department, dialysis, and transplantations), adverse events, and HRS-related mortality. Outcomes were assessed for the initial hospitalization in the base case and at 30, 60, and 90 days post-discharge.
RESULTS:
Total costs incurred over the initial hospitalization with terlipressin + ALB were lower vs NorEp + ALB, primarily due to higher ICU costs with NorEp + ALB ($7,433 vs $61,897). TER + ALB was associated with higher total costs vs MID/OCT + ALB due to higher pharmacy costs with terlipressin + ALB. The cost per complete response achieved of terlipressin + ALB ($451,605) was half that of NorEp + ALB ($930,571) and one-tenth that of MID/OCT + ALB ($4,942,123).
CONCLUSIONS:
HRS patients treated with terlipressin experienced better clinical outcomes and a lower cost per treatment response vs other unapproved treatments. ICU days and pharmacy costs were key cost drivers distinguishing the treatment groups. These outcomes suggest that terlipressin is cost-effective on the basis of total cost per response achieved.
100 Deals associated with Maxacalcitol
Login to view more data
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Psoriasis | JP | 08 Dec 2008 | |
| Impetigo | JP | 25 Nov 2008 | |
| Ichthyosis | JP | 20 Jun 2001 | |
| Keratoderma, Palmoplantar | JP | 20 Jun 2001 | |
| Psoriasis vulgaris | JP | 20 Jun 2001 | |
| Hyperparathyroidism, Secondary | JP | 03 Jul 2000 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 255 | (Paricalcitol) | iuffzrsjgv(litdobrdjy) = sykaxykkhn hjmqeykxgu (gbpwpbqiak, cvlimeniip - edqleoixsx) View more | - | 06 Jun 2013 | ||
(Maxacalcitol) | iuffzrsjgv(litdobrdjy) = chmortlysn hjmqeykxgu (gbpwpbqiak, igbakexlul - gprxxfynsy) View more | ||||||
Not Applicable | Parathyroid Diseases intact parathyroid hormones (iPTH) | - | Cinacalcet with Maxacalcitol | zdxnhirfla(fomoqoypox) = emxpkwuqvs spuvfkezpo (jqbeqsluor, 3.3) View more | Negative | 30 Oct 2012 | |
Not Applicable | 53 | zdbqvxwfpv(vmlfbywykk) = 7.5% increase in all of the parathyroid glands rmecazxojp (gbtliqpmoo ) View more | Positive | 16 Nov 2010 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free